Evercyte to showcase immortalized cell advances at BIO Europe

Vienna, Austria: – Evercyte, the leading European manufacturer of cell-based products will showcase its latest standardized, relevant cell systems at the BIO-Europe 2014 conference opening November 3 in Frankfurt, Germany.

Evercyte will share the LISA (Life Science Austria) podium, Stand 074, at Portalhaus Messe with several other innovative Austrian-based life sciences companies.

Human cell-based models

Evercyte founders and directors Regina and Johannes Grillari will take part in the partnering events as well as be on the stand throughout the convention to discuss Evercyte’s services, offer advice and discuss individual customer requirements.

In particular, the company will be able to present a portfolio of significant advances in its capacity to undertake high quality large-scale production of immortalized cell materials that allow customers to develop standardized, relevant and reproducible cell based human model systems and assays.

IPS technology

“We look forward to once again attending BIO-Europe,” said Dr. Regina Grillari, CTO. “This is a wonderful annual event that brings together the world’s leading biotechnology companies and professionals to create a convention that offers us a great opportunity to network with existing clients and create new business relationships.”

Dr. Johannes Grillari, Evercyte’s Chief Scientific Officer of Evercyte, added: “Life sciences advances derived from stem cell research and recent advances in IPS technology make our core expertise and advances in systematically establishing and characterizing innovative, immortalized human cultures for cell-based assays more relevant and compelling than ever before.”

About Evercyte

Evercyte GmbH is a spin-off company of the University of Natural Resources and Life Sciences, Vienna (BOKU-VIBT). It was founded to offer immortalized cells that retain their primary-like human cell characteristics for pharmaceutical R&D. Evercyte’s mission is to accelerate drug discovery and development by developing immortalized cells and cell lines that retain their parental characteristics.

The Vienna-based laboratory manufactures a range of cell-based products, including primary-like telomerase (hTERT) immortalized or life span extended cells, with cells differentiated from immortalized or normal stem cells. It has developed highly relevant human cell models such as RPTEC/TERT1 for kidney studies, along with colon, bronchial and kidney epithelial cells. The company also markets customer-tailored cells including keratinocytes, melanocytes or endothelial cells as well as podocytes for drug screening strategies.

Recently Evercyte entered the market for induced pluripotent stem cells by establishing human urine as a fully non-invasive method to generate relevant cellular model systems. Systematically establishing and commercializing relevant cell model systems from donors of different genetic backgrounds, Evercyte’s Pharmacocellomics™ is also improving the predictability of substance efficiencies and side effects in the general population.

The company’s services include customer-tailored immortalized cell strain development as well as cell based assay development.

About BIO-Europe Autumn 2014

The annual BIO-Europe is EBD Group’s flagship partnering conference for the biopharmaceutical and life sciences industries.

The 2014 Bio-Europe event is being held on November 3-5 at the Portalhaus Messe exhibition center in Frankfurt-am-Main and marks the 20th anniversary of the event.

BIO-Europe has been running since 2005 and consistently attracts top international executives from established and emerging pharma and biotech companies, along with academic researchers and private investors including venture capital and private equity and organizations developing companion diagnostics.

More than 3,200 delegates representing almost 1,850 companies from 56 countries attended the 19th annual BIO-Europe conference held in Vienna, Austria. The 2013 event also featured more than 180 presentations and 18 workshops or panels. This represented more than ten per cent growth over the previous year.

The event is organised by EBD Group, whose sophisticated web-based partneringONE system was last year used to facilitate almost 18,000 one-to-one meetings, with some 3,600 licensing opportunities posted.

More information at: http://www.ebdgroup.com/bioeurope/index.php